1.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021002, NCT00147537
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 10 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021020, NCT00560235
|
|
3.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021011, NCT00313781
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021006, NCT00560560
|
|
5.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021010, NCT00474760
|
|
6.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021015, NCT00560573
|
|
7.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 to 74
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021019, Japan CTPN 19-2409, NCT00603538
|
|
8.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A7471004, NCT00728390
|
|
9.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021024, NCT00729833
|
|
10.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-091, NCT00927966
|
Mobile | Español
